Prediabetes is a medical condition in which blood sugar levels are elevated above the normal range but not high enough to be classified as type 2 diabetes. Fasting blood glucose levels typically range from 100 to 125 mg/dL in individuals with prediabetes. This condition suggests early issues with blood sugar regulation, often resulting from insulin resistance. Although prediabetes usually presents without clear symptoms, it greatly increases the risk of progressing to type 2 diabetes, as well as developing cardiovascular diseases and stroke if not properly managed. However, adopting healthier lifestyle habits—such as a balanced diet, regular physical activity, and maintaining a healthy weight—can effectively prevent or delay its progression.

According to SPER market research, ‘Global Prediabetes Market Size- By Drug Class, By Age Group - Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Prediabetes Market is predicted to reach 1021.93 million by 2034 with a CAGR of 11.19%.

Drivers:

The prediabetes market is witnessing consistent growth, fueled by a combination of contributing factors. A major driver is the global increase in obesity and physical inactivity, both of which elevate the risk of developing prediabetes. The aging population and rapid urbanization are also leading to a higher incidence of the condition. Furthermore, enhanced healthcare accessibility and rising awareness of the serious health risks linked to untreated prediabetes—such as type 2 diabetes and heart disease—are prompting more individuals to undergo screening and begin early treatment. The growing adoption of effective medications like Metformin and GLP-1 receptor agonists is also broadening the range of available treatment options.

Request a Free Sample Report: https://www.sperresearch.com/report-store/prediabetes-market?sample=1

Restraints:

The global prediabetes market faces a number of obstacles that limit its overall growth. A key issue is the high rate of underdiagnosis, as prediabetes often lacks noticeable symptoms, leaving many individuals unaware they are affected. This is further exacerbated by low public awareness and inadequate routine screening, especially in low-resource and developing regions. Inequities in access to healthcare, diagnostic technologies, and regular monitoring contribute to inconsistent detection and treatment worldwide. Moreover, most current treatments are repurposed from type 2 diabetes therapies, with few drugs specifically approved for prediabetes, reducing the availability of targeted treatment options.

In 2024, North America dominated the prediabetes market, largely due to the rising use of GLP-1 agonists and an increased emphasis on personalized treatment approaches. GLP-1 agonists have gained popularity for their proven ability to regulate blood sugar and support weight loss, making them a preferred option in prediabetes care. Additionally, the expanding adoption of personalized medicine—tailoring treatments based on an individual's genetic profile and lifestyle—has enhanced the effectiveness of interventions. These developments have significantly improved prediabetes management and fueled market growth across the region. Some significant market players are Boston Pharmaceuticals, APHAIA PHARMA AG, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc.

For More Information, refer to below link: –  

Prediabetes Market Growth

Related Reports:  

Global Intravenous Immunoglobulin Market Size

Global Veterinary Eye Care Market Growth

Follow Us – 

LinkedIn | Instagram | Facebook | Twitter 

Contact Us: 

Sara Lopes, Business Consultant — USA 

SPER Market Research 

[email protected] 

+1–347–460–2899